Abstracts tagged "ACPA"

Abstract Number: 3253 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Antibodies to Cyclic Citrullinated Peptide in Two Prospective Early Rheumatoid Arthritis Cohorts 10 Years Apart
Alf Kastbom¹, Michael Ziegelasch¹, Ingrid Thyberg¹, Birgir Arge², Klara Martinsson¹, Olle Svernell³, Åsa Häggström⁴, Per Salomonsson⁵, Britt-Marie Nyhäll-Wåhlin⁶, Sören Transö⁷, Claudia Jacobs⁸ and Thomas Skogh¹, ¹IKE/Rheumatology, Linköping University, Linköping, Sweden, ²Rheumatology clinic, Eskilstuna Hospital, Eskilstuna, Sweden, ³Rheumatology Dpt, Västervik Hospital, Västervik, Sweden, ⁴Rheumatology clinic, Kalmar Hospital, Kalmar, Sweden, ⁵Rheumatology Clinic, Örebro University Hospital, Örebro, Sweden, ⁶Department of Rheumatology, Falun Hospital, Falun, Sweden, ⁷Rheumatology Clinic, Ryhov Hospital, Jönköping, Sweden, ⁸Rheumatology Dept, Oskarshamn Hospital, Oskarshamn, Sweden
Background/Purpose: Antibodies to cyclic citrullinated peptides (anti-CCP) associate with a more severe rheumatoid arthritis (RA) disease course, and therefore have influence on therapeutic decisions. By…
Abstract Number: 151 • 2015 ACR/ARHP Annual Meeting
Residual Synovitis in Ultrasound (US) Is Associated with an Evolution Towards Rheumatoid Arthritis (RA) in Patients with Inflammatory Polyarthralgia without ANTI-Citrulinated Antibodies (ACPA)
Pascal Zufferey^1,2,3, Claudia Rebell Jr.⁴, Alexandre Dumusc⁵, Mauro lucini⁴, Juerg Hains⁶, Alexander K. So Sr.⁷ and Charles Benaim⁸, ¹Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ²Pierer Decler, Chuv, Lausanne, Switzerland, ³Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ⁴DAL, RHU/CHUV, lausanne, Switzerland, ⁵RHU/CHUV, lausanne, Switzerland, ⁶DAL, RHU/CHUV, Lausanne, Syria, ⁷Service De Rhumatologie, CHUV, Lausanne, Switzerland, ⁸DAL, MPR, Lausanne, Switzerland
Background/Purpose: In ACPA positive patients, subclinical synovitis as observed by US has been demonstrated in pre RA patients and seems to be predictive for future…
Abstract Number: 1618 • 2015 ACR/ARHP Annual Meeting
The Protective Effect of HLA-DRB1*13 Alleles during Specific Phases in the Development of ACPA-Positive RA
J. van Heemst¹, A.H. Hensvold², X. Jiang², H. van Steenbergen¹, L. Klareskog², T. W. J. Huizinga¹, A.H.M. van der Helm- van Mil¹, A.I. Catrina², René E. M. Toes¹, K. Lundberg² and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Karolinska Institute, Stockholm, Sweden
Background/Purpose: HLA-DRB1*13 alleles are associated with protection from anti-citrullinated protein antibody (ACPA-)positive rheumatoid arthritis (RA). It is however unknown at which phase of disease development…
Abstract Number: 2797 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Proteins Antibodies Promotes Osteoclastogenesis and Bone Destruction in Rheumatoid Arthritis
Akilan Krishnamurthy¹, Vijay Joshua¹, Heidi Wähämaa¹, Catia Cerqueira¹, Lars Klareskog², Vivianne Malmström³, Jimmy Ytterberg¹ and Anca I Catrina¹, ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Presence of anti-citrullinated protein antibodies (ACPA) is a major risk factor for bone erosion in rheumatoid arthritis (RA) and antibodies against modified citrullinated vimentin…
Abstract Number: 450 • 2014 ACR/ARHP Annual Meeting
The Mucosal Anti-Citrullinated Protein Antibody Response in Pre-Clinical Rheumatoid Arthritis
Anneke van der Horst¹, Ivy Y.K. Choi², Dirkjan van Schaardenburg³, D.M Gerlag², Paul Tak², Dörte Hamann¹ and Rogier M. Thurlings², ¹Sanquin Diagnostic Services, Amsterdam, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands
Background/Purpose Recent data suggest rheumatoid arthritis (RA) may originate from an autoimmune response in inflamed mucosa. RA is associated with gingival and airway inflammation and…
Abstract Number: 2456 • 2014 ACR/ARHP Annual Meeting
Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression
Marshall Davis¹, Tricia LeVan², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Kaleb Michaud⁷, Geoffrey M Thiele⁸ and Ted R. Mikuls⁴, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Univ of Nebraska Med Ctr, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷National Data Bank for Rheumatic Diseases, Wichita, KS, ⁸Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA). In this study,…
Abstract Number: 449 • 2014 ACR/ARHP Annual Meeting
Citrullinated-Vimentin-Specific Regulatory T-Cell Responses Associate with ACPA Positive Individuals with Non-Specific Musculoskeletal Symptoms
Aamir Aslam¹, Jackie L. Nam¹, Laura Hunt¹, Chadi Rakieh¹, Ann W. Morgan² and Paul Emery¹, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: The pathogenesis of RA can be conceptualised by sequential phases that precede the development of synovitis. Autoimmune antibody responses, including ACPA, can precede clinical…
Abstract Number: 2019 • 2014 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Clusterin, Filaggrin, Vimentin, and Fibrinogen Are Associated with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis
Jan M. Hughes-Austin¹, Ryan W. Gan², Kevin D. Deane³, Peter K. Gregersen⁴, Michael H. Weisman⁵, Joachim H. Ix⁶, Jeremy Sokolove⁷, William H. Robinson⁸, V. Michael Holers⁹ and Jill M. Norris², ¹Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶University of California, San Diego, La Jolla, CA, ⁷VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁸VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose Hypertension is common in rheumatoid arthritis (RA), but it is unclear whether this prevalence is due to RA-related medications or to the disease process…
Abstract Number: 448 • 2014 ACR/ARHP Annual Meeting
Citrulline-Specific Autoimmunity Resides in Quiescent Circulating Memory B Cells in Rheumatoid Arthritis
Adam Pelzek, Caroline Grönwall, Jeffrey D. Greenberg and Gregg J. Silverman, Medicine, New York University School of Medicine, New York, NY
Background/Purpose . The detection of anti-citrullinated protein antibodies (ACPA) aids RA diagnosis, while B cell depletion by anti-CD20 can provide clinical benefits. We therefore undertook…
Abstract Number: 1740 • 2014 ACR/ARHP Annual Meeting
Predicting the Evolution of Inflammatory Arthritis in ACPA-Positive Individuals: Can T-Cell Subsets Model Help?
Laura Hunt¹, Agata Burska², Elizabeth M.A. Hensor¹, Jackie L. Nam¹, Frederique Ponchel¹ and Paul Emery¹, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., Leeds, United Kingdom
Background/Purpose: ACPA+ individuals with non-specific musculoskeletal symptoms are at high risk of developing rheumatoid arthritis (RA). We previously demonstrated dys-regulation of T-cell subsets with loss…
Abstract Number: 447 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Isotypes in Relation to Antibodies Against Citrullinated Peptides in Individuals before Onset of Rheumatoid Arthritis
Mikael Brink¹, Monika Hansson², Linda Mathsson-Alm³, Johan Rönnelid³, Lars Klareskog² and Solbritt Rantapää-Dahlqvist⁴, ¹Public Health & Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁴Public Health & Clinical Medicine/Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden
Background/Purpose The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) has been shown to precede the development of rheumatoid arthritis (RA) by…
Abstract Number: 1738 • 2014 ACR/ARHP Annual Meeting
Prominent Role of CCR6+ T Helper Cells in the Pathogenesis of ACPA+ Patients with Early RA
Sandra M.J. Paulissen¹, Jan Piet van Hamburg², Nadine Davelaar², Heleen Vroman³, Johanna MW Hazes⁴, P.H.P. de Jong⁵ and Erik Lubberts², ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology and Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁵Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Presence of serum anti-citrullinated protein antibodies (ACPAs) in patients with rheumatoid arthritis (RA) predicts worse disease course and a more erosive disease. In the…
Abstract Number: 453 • 2014 ACR/ARHP Annual Meeting
In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA
Jerry A. Molitor¹, Bryan S. Michalowicz², Ryan T. Demmer³, Jane H. Buckner⁴, Mark H. Wener⁵ and William H. Robinson⁶, ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Department of Developmental and Surgical Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ³Epidemiology, Columbia Univ. Mailman School of Public Health, New York, NY, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Rheumatology & Lab Med, University of Washington, Seattle, WA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Periodontal disease (PD) and RA share the risk factors HLA DR B1 shared epitope (SE) and tobacco exposure (TE). PD may represent a risk…
Abstract Number: 1465 • 2014 ACR/ARHP Annual Meeting
Follicular Helper T Cells Control Autoimmunity through IL-21/IL-21 Receptor Interaction in RA Patients
Shikha Singla¹, Minzi Chen², Jerry Pounds Jr.², Omar Khan², Jerald M. Zakem², Kismet Collins², Tamika Webb-Detiege², William E. Davis², Robert Quinet² and Xin Zhang³, ¹Rheumatology, Ochner Medical Center, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³Institute of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…
Abstract Number: 423 • 2014 ACR/ARHP Annual Meeting
Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease-Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis
Mahmood MTM Ally¹, Pieter Meyer², Bridget Hodkinson³, Eustasius Musenge⁴, Gregory Tintinger², Mohammed Tikly⁵ and Ronald Anderson¹, ¹University of Pretoria, Pretoria, South Africa, ²university of pretoria, pretoria, South Africa, ³Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, ⁴University of Witwatersrand, Johannesburg, South Africa, ⁵Rheumatology Wits University, C H Baragwanath Hospital, Johannesburg, South Africa
Background/Purpose Serial measurement of circulating anti-citrullinated peptide antibodies (ACPA) and cytokines is of potential importance in the management of patients with rheumatoid arthritis (RA). However,…

« Previous Page
1
…
7
8
9
10
11
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].